

Pascual Marco

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4029762/publications.pdf>

Version: 2024-02-01

29
papers

1,521
citations

686830

13
h-index

454577

30
g-index

34
all docs

34
docs citations

34
times ranked

1231
citing authors

#	ARTICLE	IF	CITATIONS
1	Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 622-631.	1.9	395
2	Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. <i>Blood</i> , 2012, 120, 39-46.	0.6	326
3	Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). <i>Blood</i> , 2012, 120, 47-55.	0.6	284
4	Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2012, 119, 1529-1537.	1.1	96
5	Premature myocardial infarction: Clinical profile and angiographic findings. <i>International Journal of Cardiology</i> , 2008, 126, 127-129.	0.8	67
6	Hypofibrinolysis in atrial fibrillation. <i>American Heart Journal</i> , 1998, 136, 956-960.	1.2	59
7	Premature coronary artery disease in young (age < 45) subjects: Interactions of lipid profile, thrombophilic and haemostatic markers. <i>International Journal of Cardiology</i> , 2009, 136, 222-225.	0.8	56
8	Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): Proposal for a new diagnostic paradigm. <i>Thrombosis and Haemostasis</i> , 2016, 115, 40-50.	1.8	36
9	Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): comprehensive genetic analysis by next-generation sequencing of 480 patients. <i>Haematologica</i> , 2017, 102, 2005-2014.	1.7	35
10	Von Willebrand factor and ADAMTS13 activity as clinical severity markers in patients with COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 497-503.	1.0	20
11	Effects of Body Mass Index on the Lipid Profile and Biomarkers of Inflammation and a Fibrinolytic and Prothrombotic State. <i>Journal of Atherosclerosis and Thrombosis</i> , 2015, 22, 610-617.	0.9	19
12	Management of acquired hemophilia A: results from the Spanish registry. <i>Blood Advances</i> , 2021, 5, 3821-3829.	2.5	18
13	The Unravelling of the Genetic Architecture of Plasminogen Deficiency and its Relation to Thrombotic Disease. <i>Scientific Reports</i> , 2016, 6, 39255.	1.6	15
14	Unraveling the effect of silent, intronic and missense mutations on <i>VWF</i> splicing: contribution of next generation sequencing in the study of mRNA. <i>Haematologica</i> , 2019, 104, 587-598.	1.7	13
15	Identification of 58 Mutations (26 Novel) in 94 of 109 Symptomatic Spanish Probands with Protein C Deficiency. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1409-1418.	1.8	8
16	Multiparameter Flow Cytometry Identification of Neoplastic Subclones: A New Biomarker in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma. <i>Acta Haematologica</i> , 2019, 141, 1-6.	0.7	8
17	Acquired Haemophilia: Clinical and Demographic Data. Results of European Acquired Haemophilia Registry (EACH2).. <i>Blood</i> , 2010, 116, 1398-1398.	0.6	8
18	Role of multimeric analysis of von Willebrand factor (VWF) in von Willebrand disease (VWD) diagnosis: Lessons from the PCM-EVW-ES Spanish project. <i>PLoS ONE</i> , 2018, 13, e0197876.	1.1	6

#	ARTICLE	IF	CITATIONS
19	Diurnal Variation in the Intensity of Anticoagulation in Atrial Fibrillation. Stroke, 2002, 33, 322-324.	1.0	6
20	Measurement of procoagulant activity of microparticles in plasma: Feasibility of new functional assays. Thrombosis Research, 2014, 134, 1363-1364.	0.8	5
21	Management of Bleeding In Acquired Hemophilia: Results of the European Acquired Hemophilia Registry (EACH2). Blood, 2010, 116, 716-716.	0.6	5
22	Acquired Haemophilia A and Pregnancy/Postpartum â€“ a Report From a European Registry. Blood, 2010, 116, 717-717.	0.6	5
23	Identification of new markers of recurrence in patients with unprovoked deep vein thrombosis by gene expression profiling: the retro study. European Journal of Haematology, 2016, 97, 128-136.	1.1	2
24	Unraveling the Influence of Common von Willebrand factor variants on von Willebrand Disease Phenotype: An Exploratory Study on the Molecular and Clinical Profile of von Willebrand Disease in Spain Cohort. Thrombosis and Haemostasis, 2020, 120, 437-448.	1.8	2
25	Dealing with refractoriness in obstetric primary antiphospholipid syndromeâ€”often not a matter of success. Lupus, 2014, 23, 964-965.	0.8	1
26	Involvement of antifactor VIII autoantibodies specificity in the outcome of inhibitor eradication therapies in acquired hemophilia a patients. Blood Coagulation and Fibrinolysis, 2019, 30, 127-132.	0.5	1
27	Autoimmune Acquired Factor XIII Deficiency: A Case Report. Journal of Blood Medicine, 2021, Volume 12, 63-68.	0.7	1
28	Upshaw-Schulman Syndrome: Novel homozygous missense mutation. Thrombosis Research, 2017, 158, 83-85.	0.8	0
29	Improvement in the cardiovascular profile of patients with morbid obesity following bariatric surgery. Medicine (United States), 2021, 100, e25280.	0.4	0